Illumina Introduces Genomics Solutions to Advance Clinical Research

Scalable Workflow Solutions Optimized for NGS and Microarrays

October 07, 2015 06:30 AM Eastern Daylight Time

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced the launch of new TruSeq®
library preparation kits and Infinium® arrays that enable researchers to
explore genetic variation on a more comprehensive scale. The new
additions to the application-driven portfolio address a broad range of
genetic studies from whole exome to population and disease specific
genotyping, leveraging the Illumina industry-leading portfolio of
genomic analysis systems. Illumina will highlight these new genomic
solutions at the 2015 American Society of Human Genetics meeting on
October 6 - 10 at Booth #411.

“These solutions are designed to meet the needs of researchers exploring
diverse populations and diseases, enabling them to cost-effectively
navigate a wide continuum of study types ranging from broad discovery to
routine analysis,” said Francis deSouza, President of Illumina.

The following new products are intended for use with Illumina
next-generation sequencing (NGS) systems and are complemented by new
data analysis applications available on Illumina’s BaseSpace cloud
computing platform.

TruSeq
Enrichment Portfolio (TruSeq Exome and TruSeq Rapid Exome
Library Prep Kits) One of the most widely used targeted sequencing
methods is exome sequencing, allowing efficient identification of coding
variants across a broad range of studies in cancer research, Mendelian
disease and population genetics. The TruSeq Exome kit is based on a
shearing protocol, and the TruSeq Rapid Exome kit is based on an
enzyme-mediated (transposase) protocol. The kits are compatible with a
variety of sample types, including formalin-fixed, paraffin-embedded
(FFPE) samples, and offer automation compatible, seamless workflows from
sample to variant calling.

TruSeq
Custom Amplicon Low Input Designed and optimized for use with
FFPE samples, this new product consistently delivers robust performance
at 10ng of DNA input. Additional features include a simplified, scalable
workflow protocol and 16-sample starter kit. Concurrently, Illumina is
releasing an updated version of DesignStudio™, its online custom assay
design tool. Expert design assistance and full assay optimization
support is also available through Illumina Concierge. Matched with
Illumina’s industry-leading sequencing systems, researchers can now
achieve robust data quality across genomic repeats and other
challenging-to-sequence regions of the genome.

The following new products are intended for use with Illumina’s iScan®
and HiScan® microarray platform. As with TruSeq Custom Amplicon, these
products can also be customized utilizing DesignStudio or Illumina
Concierge.

Infinium DrugDev Consortium Array Effective drug development
depends on thorough target validation and the comprehensive
understanding of drug safety and efficacy as early as possible in the
development process. Developed in collaboration with leaders in
translational genomics and computational biology, the DrugDev Consortium
Array enables researchers to perform genetic studies leveraging the
principle of Mendelian randomization to reproduce key elements of a
randomized trial. Key applications include drug target discovery and
validation, drug repurposing and drug specificity studies.

Infinium MethylationEPIC BeadChip This is the next-generation of
the HumanMethylation450 BeadChip kit and leverages new genetic content
generated as a result of the National Institutes of Health (NIH)
sponsored ENCODE (Encyclopedia of DNA Elements) research program. The
new microarray provides unparalleled coverage of CpG islands, GENCODE
genes, ENCODE open chromatin, ENCODE transcription factor binding sites
and FANTOM5 enhancers. Infinium HD technology enables content selection
independent of bias often associated with alternative methylated DNA
capture methods. The new microarray is also compatible with FFPE
samples, offers a streamlined workflow and achieves 98 percent
reproducibility for technical replicates.

Infinium ImmunoArray-24 v2.0 BeadChip This is a new addition to
Illumina’s genotyping array portfolio and is designed to detect genetic
variation in the human immune system. Applications include the research
and analysis of novel and causal variants associated with major
autoimmune and inflammatory disorders.

Infinium Multi Ethnic Array Family This provides a
cost-effective, high throughput approach for large scale population
research across diverse human populations. These new arrays leverage
expertly developed content from groups such as the Consortium on Asthma
among African-ancestry Populations in Americas (CAAPPA), Population
Architecture using Genomics and Epidemiology (PAGE), and T2D-Genes, as
well as large scale studies such as the 1,000 Genomes Project and
clinical reference databases such as Online Mendelian Inheritance in
Man, and ClinVar. Delivering excellent genomic coverage and high value
content at an affordable price, the Multi-Ethnic Array Family provides
customers with the power and pricing to effectively carry out studies
across the world’s populations.

Also at ASHG, Illumina will announce an Illumina Accelerator Sequencing
Grant competition available to applicants for the incoming Illumina
Accelerator genomic startup class. For more information on the grant
program, visit www.illumina.com/science/accelerator/grant-competition.

Illumina is transforming human health as the global leader in sequencing
and array-based technologies. The company serves customers in a broad
range of markets, enabling the adoption of genomic solutions in research
and clinical settings. To learn how Illumina is unlocking the power of
the genome, visit www.illumina.com and
follow @illumina.

Forward-Looking Statements

This release may contain forward looking statements that involve risks
and uncertainties. Important factors that could cause actual results to
differ materially from those in any forward-looking statements are
detailed in our filings with the Securities and Exchange Commission,
including our most recent filings on Forms 10-K and 10-Q, or in
information disclosed in public conference calls, the date and time of
which are released beforehand. We do not intend to update any
forward-looking statements after the date of this release.